摘要
目的分析孟鲁司特钠联合布地奈德对哮喘急性发作(acute asthma,AS)临床疗和对血清IL-4及IFN-γ的影响。方法回顾天津市第一医院收治的83例AS患者并依照治疗分为对照组(n=40)和观察组(n=43),对照组采用布地奈德雾化治疗,观察组在对照组基础上联合孟鲁斯特钠进行治疗(10 mg/次,睡前服用)。分析治疗后临床效果、肺功能及不良反应发生率等有无差异。结果观察组与对照组有效率分别为93.02%和72.50%,差异有统计学意义(P<0.05);观察组治疗后FEV1/FVC、PEF和IFN-γ均显著高于对照组治疗后(P<0.05);两组患者治疗后血清IL-4水平和症状积分均显著低于治疗前(P<0.05);两组恶心呕吐不良反应发生率差异无统计学意义(P>0.05)。结论孟鲁司特钠联合地奈德治疗AS可提供肺功能,改善临床症状,不良反应较轻。
Objective To analyze the effects of montelukast and budesonide on the treatment of Acute asthma(AS)and serum IL-4 and IFN-γ.Methods 83 AS patients were retrospectively divided into control group(n=40)and observation group(n=43)according to treatment.The control group was treated with budesonide atomization,and the observation group was treated with montelast(10 mg/time,before bed)on the basis of the control group.The clinical effect,lung function and incidence of adverse reactions were analyzed.Results The effective rates of observation and control group were 93.02%and 72.50%,respectively(P<0.05).FEV1/FVC,PEF and IFN-γin observation group were significantly higher than those in control group after treatment(P<0.05).Serum IL-4 level and symptom score in 2 groups after treatment was significantly lower than before(P<0.05);There was no statistical difference in the incidence of nausea and vomiting between the two groups(P>0.05).Conclusion Montelukast and budesonide can improve lung function and clinical symptoms in the treatment of AS.
作者
赵菁
李翊
ZHAO Jing;LI Yi(Department of Pharmacy,Tianjin First Hospital,Tianjin 300232,China;The Second Department of Internal Medicine,Tianjin First Hospital,Tianjin 300232,China)
出处
《继续医学教育》
2022年第2期89-92,共4页
Continuing Medical Education
